ARDELYX, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
ARDELYX, INC. (ARDX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 20.60% for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-17.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2017-02-17
- ARDELYX, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2014 was 20.60%, a 0.96% decline from fiscal 2013.
- ARDELYX, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2013 was 20.80%, a 300.00% increase from fiscal 2012.
- ARDELYX, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2012 was 5.20%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2014-12-31 | 20.60% 10-K · filed 2017-02-17 |
| 2013-12-31 | 20.80% 10-K · filed 2016-03-04 |
| 2012-12-31 | 5.20% 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |